Beware of Counterfeits
Bayer HealthCare is engaged in protecting patients from drug counterfeiting
Counterfeit drugs have developed into a serious global problem in recent years. Even in countries with a safe system for marketing medicinal products, patients must know their risks. Counterfeit drugs can endanger the health of unsuspecting users or can even be life-threatening. Bayer HealthCare regards it as its duty to stand up for patient safety in face of the threat posed by counterfeit drugs. The company has launched the “Beware of Counterfeits” campaign.
Everything that Bayer HealthCare does, with its annual research expenditure running into billions of euros, is designed to guarantee that patients are optimally supplied with high-quality products and to ensure that the company’s good reputation is not harmed by counterfeit products. Bayer HealthCare is making its contribution to combating the problem of counterfeiting by means of product-based security measures, internal and external investigators, and prosecution of offenders.
Success in this field requires joint efforts by the industry and its associations, as well as by state and supranational organizations. Bayer HealthCare therefore cooperates with the responsible authorities worldwide and actively supports, for example, the anti-counterfeiting activities of the World Health Organization’s International Medical Products Anti-Counterfeiting Taskforce (IMPACT) and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The company is a member of the Pharmaceutical Security Institute, the German Aktionskreis Produkt- und Markenpiraterie (Action Group Against Product and Brand Piracy), and many other initiatives at the national level devoted to the fight against drug counterfeiting.